Polar Anionic Polymers rescue AD by inhibiting Aβ/PrP

• Amyloid β-oligomers (Aβ) bind to neurons via Prion Protein (PrP), triggering neurotoxic cascade and Alzheimer’s disease
• Polar anionic polymers bind to PrP with high affinity, inhibiting Aβ binding
• Oral delivery of PSCMA (Polymer 3) inhibits the Aβ/PrP interaction and rescues Alzheimer’s Disease-induced learning and memory deficits in mice
• Pending Patent: US 62/694710
• Innovators: Stephen M. Strittmatter, M.D., Ph.D. Erik Christian Gunther, Ph.D.